A Retreatment Study With Bortezomib for Multiple Myeloma
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to monitor such factors as a past history, a previous history of
drug use, the degree of response to initial treatment, the frequency of previous therapies,
age, Eastern Cooperative Oncology Group (ECOG) performance status, which is used by doctors
and researchers to assess how a patient's disease is progressing, assess how the disease
affects the daily living abilities of the patient, and determine appropriate treatment and
prognosis, before the bortezomib re-treatment, the concomitant drugs that are used for
re-treatment and the pattern of treatment in patients with multiple myeloma who were
re-treated with injectable bortezomib.